Lupin Ltd (LUPIN) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Lupin had a stellar FY25, continuing growth momentum and evolving strategic growth drivers.
- The company achieved USD 2.7 billion in revenue and USD 625 million in EBITDA.
- Lupin holds leadership positions in key markets, ranking 3rd in the US by prescriptions dispensed, 8th in India (organically), 4th in Australia, and 8th in South Africa for generics.
- The business is geographically diversified, with Developed Markets and Emerging Markets each contributing roughly 50% of revenue.
- The company made significant progress on ESG initiatives.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.